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964Abstract: The presence of bimodal outcome distributions has been used as a justification for con-
ducting responder analyses, in addition to, or in place of analyses of the mean between-group differ-
ence, in clinical trials and systematic reviews of interventions for pain. The aim of this study was to
investigate the distribution of participants’ pain outcomes for evidence of bimodal distribution. We
sourced data on participant outcomes from a convenience sample of 10 trials of nonsurgical interven-
tions (exercise, manual therapy, medication) for spinal pain. We assessed normality using the
Shapiro-Wilk test. When the Shapiro-Wilk test suggested non-normality we inspected distribution
plots visually and attempted to classify them. To test whether responder analyses detected a mean-
ingful number of additional patients experiencing substantial improvements we also calculated the
risk difference and number needed to treat to benefit. We found no compelling evidence suggesting
that outcomes were bimodally distributed for any of the intervention groups. Responder analysis
would not meaningfully alter our interpretation of these data compared with the mean between
group difference. Our findings suggest that bimodal distribution of outcomes should not be assumed
in interventions for spinal pain and do not support the automatic prioritization of responder analysis
over the between group difference in the evaluation of treatment effectiveness for pain.
Perspective: Secondary analysis of clinical trials of nonsurgical interventions for spinal pain found
no evidence for bimodally distributed outcomes. The findings do not support the automatic prioriti-
zation of responder analyses over the average between group difference in the evaluation of treat-
ment effectiveness for spinal pain.
ª 2017 The Authors. Published by Elsevier Inc. on behalf of the American Pain Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key words: Pain, clinical trials, systematic reviews, effectiveness.andomized controlled trials (RCTs), and systematic
reviews of RCTs are widely considered the most
robust method to evaluate the efficacy and effec-
tiveness of clinical interventions. In pain treatment a crit-
ical outcome is pain intensity, which is commonly
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.doi.org/10.1016/j.jpain.2017.03.004or numeric rating scale. In RCTs with outcomes measured
on these scales, the only direct estimate of the effects
caused by the intervention of interest is the average be-
tween group difference in pain score after the interven-
tion. For example, if a hypothetical RCT, comparing an
electrotherapy intervention with a placebo control, re-
ported a postintervention between group mean differ-
ence of 1 point on a 0 to 10 pain intensity VAS, then we
would interpret that the intervention specifically
improved pain by 1 point, on average.
A range of examples from trials of pharmacologic ther-
apies for pain show that that the pattern of participant
outcome is often bimodally distributed.21,23,24 Simply
put, of the patients who receive the active intervention
some experience substantial improvement (and are
often referred to as ‘‘responders’’), some have minimal
to no change in their outcome (‘‘nonresponders’’), and
very few experience intermediate (moderate) effects.
O’Connell et al The Journal of Pain 965This bimodality of outcomes is proposed to reflect that
these interventions deliver large treatment effects for a
minority of patients and that this large benefit to those
individuals is essentially washed out in the between-
group average difference, because of the large propor-
tion of nonresponders, leading to underestimation
of the effectiveness of the intervention. In this instance,
the average treatment effect, estimated according to
the between group difference, may not reflect the expe-
rience of many or indeed any participants who received
the intervention. On that basis it has been proposed
that in trials for chronic pain, the mean between group
difference lacks utility as ameasureof effectiveness.22,24,25
One proposed solution to this problem is to conduct a
‘responder analysis,’9,10,22,24,25 which compares the
proportion achieving a predetermined clinically
important improvement from baseline in the treatment
and control groups. It is proposed that this type of
analysis better quantifies individual participant
responses to treatment, enables the calculation of easily
interpreted measures such as the number needed to
treat to benefit (NNTB)9,10,22,24,25 and thereby provides
more meaningful and interpretable estimates of
treatment effectiveness than the between group mean
difference. Such analyses can use thresholds for
important change derived from patients. For example,
the Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) consensus group
recommendations5 use benchmarks on the basis of studies
that compared pain scores with global impression of
change in patients with neuropathic pain,7 arthropa-
thies,27 and pain after spinal cord injury or amputation.13
In responder analysis of clinical trials, the between
group difference in the proportion of participants who
experience a good outcome reflects the net increase in
the proportion of patients who achieve the desired
outcomebecauseof the intervention. However, responder
analyses have attracted criticism over certain conceptual
and practical limitations. The term ‘‘responder analysis’’
encourages the conflation of patient outcomeswith treat-
ment effects.28 ‘Responders’ are identified by within per-
son change from baseline. That change (or outcome)
maybe because of natural recovery, nonspecific treatment
effects, and/or regression to themeanaswell as, or instead
of, the effects of the intervention and it is not possible to
isolate treatment effects from these other causes ofwithin
person change.14 As such, the label ‘‘responder’’ simply
identifies a participant whose outcome improved, regard-
less of whether improvement was because of the treat-
ment or not. In fact, treatment may be responsible for
very little, or none of that improvement in outcome. It is
also possible that some individuals who actually re-
sponded to the intervention might not be counted as re-
sponders. For example, if the natural history of a person
during the treatment period would have been significant
worsening, yet with treatment their condition remains
stable, they will be counted as nonresponders despite
receiving significant benefit from the intervention. Simi-
larly, a lack of symptom improvement and significant
worseningof symptoms areboth counted simply as nonre-
sponse. Finally, the dichotomization of outcomes inresponder analyses greatly reduces the precision of esti-
mates of effect, necessitating larger sample sizes to detect
significant differences.28
Fig 1 illustrates this issue. Data from the treatment arm
of a hypothetical RCT are bimodally distributed with a
small but distinct group of ‘‘responders’’ achieving sub-
stantial ($50%) pain relief. Because a larger group
achieves little or no relief the average reduction in pain
in this group is small. In Fig 1B the control group data
are added and are unimodally distributed. In this example
the between group average difference in pain relief is
small because of the large number in the treatment group
who experienced little pain relief. In this case, a treatment
that is actually effective for a certain group of people
might be considered not meaningfully better than con-
trol, on the basis of a small mean between group differ-
ence. In this instance a case can be made that a
responder analysis is more informative than the average
between group difference in pain scores.
Examples of bimodal outcome distributions have been
reported in selected examples of pharmacological inter-
ventions for pain21,23,24 but it has not yet been
established whether this pattern is commonly present
across a wide range of interventions. As such, the case
for the wider replacement of the between group
difference with responder analysis in trials and reviews
of interventions for pain has not been established. One
finding that would support such a case would be the
observation of bimodal outcome distributions (expressed
as percentage change from baseline) in groups
receiving various different types of interventions. This
case would be further supported if the equivalent
outcomes from placebo, waiting list, or minimal care
control groups did not also show a bimodal outcome
distribution, because evidence of bimodal outcomes is
not in itself evidence of bimodal effects. When outcomes
are normally distributed in all groups or similarly
distributed in intervention and control groups, it is
likely that the average between group effect remains
the most representative and informative estimate of
treatment effectiveness.
Aim
The aimof our exploratory studywas to investigate the
distribution of participants’ pain outcomes using data
from a selection of trials of nonsurgical interventions
for spinal pain.
Methods
This was a secondary analysis of data from recent trials
of different interventions for spinal pain.We sourced data
on participant outcomes froma convenience sample of 10
trials of nonsurgical interventions for low back and neck
pain conducted by researchers at the George Institute
for Global Health that measured pain intensity as a pri-
mary outcome. Our analysis included all relevant trials
conducted by this group over a 9-year period.
For each trial, we calculated the percentage change in
pain intensity score from baseline to the first follow-up
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Figure 1. Impact of bimodally distributed outcomes. Hypothetical data from an active intervention arm of an RCT. A small propor-
tion of participants experience substantial ($50%) pain relief in the intervention whereas most experience little improvement.
Becausemost participants experience little or no change the estimate of average pain relief experienced is modest. The control group
data are superimposed (red). Outcomes are unimodally distributed in this group. The difference in average pain relief between
groups is small despite the presence of more ‘‘responders’’ in the active group.
966 The Journal of Pain Distribution of Outcomes in Clinical Trials of Nonsurgical Interventionsin the trial.We then aggregated these to create a distribu-
tion of change scores (outcomes) for each arm of the trial.
We divided the samples according to duration of pain
(acute and chronic) and pooled data according to the
type of intervention. Before combining data from
different trials we checked, using visual inspection, that
baseline pain scores were similarly distributed. When
this was the case we combined data from different trials
in the following groups, established a priori:
1. Exercise interventions,
2. Manual therapy interventions,
3. Medications, and
4. Placebo/sham control, minimal intervention con-
ditions.
Data from all comparison/control groups (placebo/
sham, wait list, minimal care) were combined. For drop-
outs, missing data were imputed using the baseline
observation carried forward method.
Tests for normality of the outcome distribution were
conducted using the Shapiro-Wilk test. When these tests
suggested non-normality we inspected the distribution
plots visually and attempted to classify them. When sepa-
rate distribution peaks suggestive of groups with distinct
distributions were observed we planned to assign a cut
point (‘‘knot’’), decided post hoc upon observation of the
data and consider whether distributions on each side of
the knot followed known parametric distributions, for
example, normal, binomial, or Poisson distribution. How-
ever, we did not observe such distinct peaks in our data
sothiswasnotconducted.Weconducteda sensitivityanal-
ysis to examine the effect of imputing missing data by re-
analyzing the data using an available case approach. No
adjustment was made for baseline levels of pain intensity.In a secondary analysis we tested the proposition that
small average between group treatment effects in our
data set might hide the fact that a meaningful number
of additional patients experienced substantial improve-
ments above what they would have received in the com-
parison condition. Using the IMMPACT group
recommend thresholds of 30% and 50% improvement
from baseline5 as markers of moderately and substan-
tially important change, respectively, we calculated the
risk difference (absolute risk increase or decrease) and
number needed to treat for all trials that reported an
average between group difference of <10 mm or 1 point
on a 100-mm 10-point pain scale. This threshold was cho-
sen on the basis of the recent Outcome Measures in
Rheumatology (OMERACT12) consensus group recom-
mendations for a threshold to define a minimal clinically
important effect.3Results
Description of Included Studies
Data were available from 10 RCTs published between
2007 and 2015 that included a total of 2,926 participants
and were conducted by the George Institute for Global
Health and the University of Sydney. In acute pain condi-
tions we included data from 3 RCTs12,17,32 and in chronic
pain conditions we included 6 RCTs.4,8,11,16,20,29 One
study26 recruited participants with subacute low back
pain, with pain of 6 to 12 weeks duration; we included
this study in the chronic category but conducted a sensi-
tivity analysis to see whether its exclusion from this
group affected our results.
Table 1. Included Trials According to
Intervention Group
ACUTE/CHRONIC INTERVENTION TRIALS INCLUDED
POOLED N
FOR GROUP
Acute Placebo Williams et al32
Hancock et al12
606
Exercise Machado et al17 74
Manual therapy Hancock et al12 60
Medications Williams et al32
Hancock et al12
1,154












Manual therapy Ferreira et al8 80
O’Connell et al The Journal of Pain 967Interventions included exercise interventions (Tai Chi,
motor control exercise, McKenzie spinal exercises, multi-
modal exercise, graded activity), manual therapy (spinal
manipulative therapy), medication (paracetamol 665 mg
modified-release regular dose plus placebo tablets ‘‘as
needed,’’ or 665 mg modified-release regular dose and
500 mg paracetamol immediate-release tablets ‘‘as
needed,’’ diclofenac 50 mg twice daily). Placebo/minimal
care control interventions included placebo tablets, a sin-
gle advice session and booklet, and detuned electro-
therapy. Two trials included participants with whiplash-
associated disorder20,29 and 8 included participants with
low back pain.4,8,11,12,16,17,26,32 Table 1 outlines the
included trials and interventions contributing to the anal-
ysis and Table 2 summarizes the characteristics of partici-
pants in the included trials.Distributions of Outcomes
Acute
Participant outcomes were not normally distributed
for any of the groups (Shapiro-Wilk test for all groups








Costa et al4 154 53.7 (12.8) 93 (60.4) Chro
Ferreira et al8 240 53.7 (14.9) 165 (68.8) Chro
Hall et al11 160 43.4 (13.3) 119 (74.4) Chro
Hancock et al12 239 40.7 (15.6) 105 (43.9) Acut
Macedo et al16 172 49.2 (15.0) 102 (59.3) Chro
Machado et al17 148 46.6 (14.7) 74 (50.0) Acut
Michaleff et al20 172 42.9 (12.4) 110 (64.0) Chro
Pengel et al26 259 49.9 (15.8) 124 (47.9) Suba
Stewart et al29 134 43.3 (14.7) 89 (66.4) Chro
Williams et al32 1,643 45.0 (15.8) 766 (46.6) Acut
Abbreviations: LBP, low back pain; WAD, whiplash associated disorder; n/a, not avai
NOTE. Acute defined as <6 weeks, subacute as 6 to 12 weeks, and chronic as >12 wwas observed for any of the groups (Fig 2). Distributions
generally showed a unimodal distribution with a strong
positive skew reflecting that most participants in these
trials experienced complete or substantial improvement
in their pain, whichever group there were assigned to,
including placebo and minimal care groups. Participants
receiving exercise interventions showed a broader and
more variable distribution.
Chronic
Participant outcomes were not normally distributed for
any of the groups (Shapiro-Wilk test for all groups P < .05;
Table 3). No clear evidence of bimodal of distribution was
observed. The placebo/minimal care and exercise group
distributions were unimodal with a positive skew (Fig 3)
with the peak of the distribution reflecting thatmost par-
ticipants experienced little change from baseline. The
manual therapy distribution showed a broader and
more random distribution but without strong evidence
to suggest bimodality. Reanalyzing with data from the
study of Pengel et al26 removed did not alter the results.
Sensitivity Analysis
Reanalysis of all groups using an available case
approach instead of imputingmissing data using baseline
observation carried forward did not reveal evidence of
bimodal distribution for any of the intervention classes.
Secondary Analysis
We calculated the risk difference and NNTB for compar-
isons that showed small (<1 point change on a VAS) be-
tween group mean differences. These results are shown
in Tables 4 and 5. In our sample, no comparisons with
between group differences <1 showed statistical
significance at the P < .05 level. Similarly, the NNTB were
frequently high (>10) with 95% confidence intervals (CIs)
that crossed the line of no effect for all comparisons.Discussion
In this sample of RCTs of interventions for spinal pain
we found no compelling evidence suggesting that out-
comes are bimodally distributed for the interventions








nic LBP 331.5 (392.4) Wk 6.7 (2.0) 8 Wk
nic LBP 103.1 (120.7) Mo 6.3 (2.0) 8 Wk
nic LBP n/a 4.4 (2.0) 8 Wk
e LBP 9.1 (9.3) D 6.5 (1.7) 4 Wk
nic LBP 87.7 (105.0) Mo 6.0 (2.1) 8 Wk
e LBP n/a 6.7 (1.9) 3 Wk
nic WAD 21.5 (16.8) Mo 5.1 (2.0) 14 Wk
cute LBP n/a 5.4 (2.0) 6 Wk
nic WAD 9.0 (2.4) Mo 5.3 (2.0) 6 Wk
e LBP 9.8 (10.0) D 6.3 (1.9) 4 Wk
lable.
eeks.
Table 3. Results of Tests of Normality According
to Intervention Group (Shapiro-Wilk Test)
ACUTE/CHRONIC INTERVENTION GROUP STATISTIC DF P
Acute Placebo .691 605 <.01
Exercise .895 74 <.01
Manual therapy .660 59 <.01
Medications .715 1,154 <.01
Chronic Placebo .736 307 <.01
Exercise .776 636 <.01
Manual therapy .961 80 .016
968 The Journal of Pain Distribution of Outcomes in Clinical Trials of Nonsurgical Interventionsbetween chronic and acute conditions, with acute con-
ditions predictably showing a positively skewed, but
essentially unimodal, distribution, indicating that
most participants experienced substantial pain relief.
This pattern was the same regardless of the receipt of
any particular treatment, or control intervention. For
chronic conditions outcome distributions did not
meet the threshold for normality as per the Shapiro-
Wilk test, but were more evenly spread frommild wors-
ening, to little or no change, to mild or moderate
improvement.
Recommendations to prioritize or at least coreport
responder analyses over the mean between group differ-Figure 2. Distribution of participant outcomes in acute pain cond
http://www.jpain.org/.ence have been made with particular regard to the
evaluation of drug therapies for pain.3,5,22,24,25 Specific
examples of bimodal distribution of outcomes have
beenpresented for: nonsteroidal anti-inflammatorydrugs
(etoricoxib and naproxen) in acute postoperative pain,
osteoarthritis pain, chronic low back pain, and ankylosing
spondylitis23; and duloxetine in osteoarthritis, fibromyal-
gia, chronic low back pain, and painful diabetic neuropa-
thy.21 In the data presented in this report we found
no evidence for bimodality of outcomes when we pooled
data from trials of paracetamol and diclofenac (n = 1,114)
for acute low back pain. In the primary analyses of both of
those trials no significant between group difference was
observed between the drug and placebo groups, suggest-
ing a lack of efficacy, which may explain the lack of
bimodal distribution. Therewas also no evidence of bimo-
dality when we investigated each drug individually or for
nonpharmacological interventions. These findings sug-
gest that bimodal distribution of outcomes for pain inter-
ventions cannot necessarily be assumed.
In our secondary analysis we sought to see if small (<1
point on a 0–10 VAS) between group differences in pain
intensity corresponded to potentially a favorable NNTB.
The proposed value of responder analysis may lie with in-
terventions for which a between group differenceitions; 1.0 = 100% pain relief. Please see this figure in color at
Figure 3. Distribution of participant outcomes in chronic pain conditions; 1.0 = 100% pain relief. Please see this figure in color at
http://www.jpain.org/.
O’Connell et al The Journal of Pain 969compared with the comparison condition is present (for
example as indicated by a threshold of statistical signifi-
cance) but where that difference is small. The absence of
statistical significance in the available comparisons in our
analysis is reflected in CIs for the risk difference and num-
ber needed to treat that all cross the line of no effect. In
these data, responder analysis would not meaningfully
alter our interpretation of the data compared with the
average between-group difference. The lack of bimo-
dality of outcomes in our data may be interpreted as re-
flecting comparisons of treatments that lack even
marginal effectiveness. The 2 comparisons in our data
set that showed as statistically significant between group
differences (Tai Chi vs waiting list control for chronic low
back pain, mean difference 1.2 (95% CI, .6–1.8).11 Advice
with exercise versus placebo for subacute low back pain,
mean difference 1.56 (95% CI, .7–2.4)26 had mean be-
tween group differences of >1 point on a pain scale
which exceeds the OMERACT 12 group’s recent recom-
mended threshold for a minimal clinically important ef-
fect. For those comparisons, outcomes in the
intervention group did not show a bimodal distribution.
Post hoc analysis of these comparisons reveals relatively a
favorable NNTB for a 50% reduction in pain of 4 (95% CI,
2–12) for Tai Chi versus usual care and 4 (95%CI, 2–26) for
advice and exercise versus placebo. In these examples a‘responder’ analysis, although offering an alternative
way to present the data, does not change our interpreta-
tion of the results compared with a traditional means
analysis. Because of the absence of bimodal distribution
in these data one interpretation may be that the be-
tween group difference may be representative of the
average true treatment effect but may have been
adequate to tip a larger number of participants over
the threshold from ‘‘non-responder’’ to ‘‘responder’’ in
the treatment group. In this way generally modest treat-
ment effects may give the false impression of large treat-
ment ‘‘responses.’’
It is clear that the mean between group difference is a
somewhat blunt toolwith limitations. It tells us little about
the individual experience of participants in clinical trials or
that factors that drive them. In certain circumstances (ie, in
which strong evidence of bimodality is present), responder
analysismay be useful although it is crucial that the thresh-
olds used to establish response have validity and are estab-
lished a priori. Despite the problems outlined previously in
establishing clinical ‘‘response,’’ it is arguable that
responder analyses offer a simple andunderstandable esti-
mate of what is likely to happen to a patient given a treat-
ment in a clinical setting and therefore useful to inform
clinician and patient decision-making. However, it remains
important to recognize its limitations as an estimate of





CHANGE IN PAIN (95% CI)* NNTB/NNTH (95% CI)y
RISK IFFERENCE 50% CHANGE
Pain (95% CI)*
NNT 50% CHANGE IN
PAIN (95% CI)y
Hancock et al12 NSAID versus SMT .71 (1.51 to .08) .03 (.17 to .11) NNTH 31 (NNTH 6 to NNTB 9) .07 (.12 to .28) NNTH 13 (NNTH 8 to NNTB 4)
NSAID versus NSAID with SMT .47 (1.28 to .08) .03 (.17 to .11) NNTH 30 (NNTH 6 to NNTB 9) .03 (.20 to .13) NNTH 30 (NNTH 5 to NNTB 8)
NSAID versus placebo .17 (.95 to .62) .03 (.17 to .11) NNTH 30 (NNTH 6 to NNTB 9) .03 (.20 to .13) NNTH 30 (NNTH 5 to NNTB 8)
SMT versus NSAID with SMT .25 (.53 to 1.02) .001 (.13 to .13) NNTH 885 (NNTH 8 to NNTB 8) .03 (.11 to .17) NNTB 31 (NNTH 6 to NNTB 9)
SMT versus placebo .55 (.20 to 1.29) .001 (.13 to .13) NNTH 885 (NNTH 8 to NNTB 8) .03 (.11 to .17) NNTB 31 (NNTH 6 to NNTB 9)
NSAID with SMT versus placebo .30 (.46 to 1.06) 0 (.13 to .13) NNT N (NNTH 8 to NNTB 8) 0 (.15 to .15) NNT N (NNTH 7 to NNTB 7)
Machado et al17 GP (control) versus McKenzie .54 (1.41 to .33) .09 (.27 to .08) NNTH 11 (NNTH 6 to NNTB 9) .16 (.36 to .04) NNTH 6 (NNTH 3 to NNTB 28)
Williams et al32 Placebo versus Paracetamol (regular
dose 1 as needed)
.17 (.21 to .46) .02 (.04 to .08) NNTB 41 (NNTH 27 to NNTB 12) .05 (.02 to .12) NNTB 21 (NNTH 43 to NNTB 8)
Placebo versus Paracetamol (regular dose) .07 (.40 to .27) .007 (.05 to .06) NNTB 128 (NNTH 19 to NNTB 15) .01 (.06 to .08) NNTB 91 (NNTH 18 to NNTB 13)
Paracetamol (regular dose 1 as needed)
versus Paracetamol (regular dose)
.19 (.53 to .15) .016 (.08 to .04) NNTH 61 (NNTH 13 to NNTB 22) .04 (.11 to .03) NNTH 28 (NNTH 9 to NNTB 29)
Abbreviations: NNTH, number needed to treat to harm; NNT, number needed to treat; NSAID, nonsteroidal anti-inflammatory drug; SMT, spinal manipulative therapy; GP eneral practitioner management.
*Negative values indicate the comparator intervention was more beneficial.
yBecause lower values of NNT represent larger effect sizes, no effect represents infinity; see Altman.1




RISK DIFFERENCE 30% CHANGE
IN PAIN (95% CI)*
NNTB/NNTH 30% CHANGE
IN PAIN (95% CI)y
R DIFFERENCE 50%
CHAN E IN PAIN (95% CI)*
NNTB/NNTH 50% CHANGE
IN PAIN (95% CI)y
Costa et al4 Motor control versus placebo .81 (.11 to 1.72) .14 (.07 to .36) NNTB 7 (NNTH 13 to NNTB 3) 08 (.12 to .28) NNTB 13 (NNTH 8 to NNTB 4)
Ferreira et al8 General ex versus specific ex .68 (1.48 to .13) .16 (.37 to .05) NNTH 6 (NNTH 3 to NNTB 19)  13 (.33 to .07) NNTH 8 (NNTH 3 to NNTB 13)
General ex versus SMT .55 (1.37 to .27) .11 (.33 to .10) NNTH 9 (NNTH 3 to NNTB 10)  13 (.33 to .07) NNTH 8 (NNTH 3 to NNTB 13)
Specific ex versus SMT .13 (.70 to .95) .05 (.17 to .27) NNTB 20 (NNTH 6 to NNTB 4) 0 (.21 to .21) NNT N (NNTH 5 to NNTB 5)
Macedo et al16 Graded activity versus motor control .12 (.73 to .96) .04 (.17 to .25) NNTB 20 (NNTH 6 to NNTB 4) . 04 (.20 to .21) NNTB 247 (NNTH 5 to NNTB 5)
Michaleff et al20 Ex versus control .12 (.59 to .82) 0 (.21 to .21) NNT N (NNTH 5 to NNTB 5) 01 (.18 to .20) NNTB 85 (NNTH 6 to NNTB 5)
Pengel et al26 Advice with ex versus advice .74 (.20 to 1.69) .12 (.11 to .34) NNTB 9 (NNTH 9 to NNTB 3) 10 (.14 to .35) NNTB 10 (NNTH 7 to NNTB 3)
Advice with ex versus ex .80 (.04 to 1.64) .125 (.10 to .35) NNTB 8 (NNTH 10 to NNTB 3) 05 (.20 to .29) NNTB 21 (NNTH 5 to NNTB 3)
Advice versus ex .52 (.81 to .91) .01 (.23 to .25) NNTB 103 (NNTH 4 to NNTB 4)  05 (.3 to .19) NNTH 18 (NNTH 3 to NNTB 5)
Advice versus placebo .81 (.05 to 1.69) .21 (.03 to .44) NNTB 5 (NNTH 34 to NNTB 2) 17 (.07 to .40) NNTB 6 (NNTH 15 to NNTB 2)
Ex versus placebo .77 (.003 to 1.53) .20 (.04 to .43) NNTB 5 (NNTH 26 to NNTB 2) 22 (.01 to .46) NNTB 5 (NNTH 102 to NNTB 2)
Abbreviations: NNTH, number needed to treat to harm; ex, exercise.
*Negative values indicate the comparator intervention was more beneficial.



































































O’Connell et al The Journal of Pain 971efficacy.When outcomes are not bimodally distributed it is
arguable as to whether responder analysis performs that
task any better.
As well as aiming to offer a more meaningful interpre-
tation of bimodally distributed outcomes, responder ap-
proaches have been recommended for identifying
potentially important characteristics of responders that
may act as effect modifiers.2 However as discussed previ-
ously, because ‘‘response’’ includes the influences of natu-
ral history, regression to the mean, and the nonspecific
effects of interventions, such approaches conflate
outcome with treatment response and risk identifying
general prognostic indicators as opposed to actual treat-
ment effect modifiers. There are alternative methods for
identifying patients who are more likely to respond to a
particular treatment thatminimize that risk. These include
exploring treatment effectmodifiers using interaction an-
alyses15,30 or by exploring proposedmechanisms of action
of different treatments using mediation analyses. These
studies can also inform clinical decision-making although
still require judgement regarding the size and likely clin-
ical importance of any observed effects.18,31
Other approaches to interpreting patient-reported out-
comes are emerging. For example, cumulative distribu-
tion functions have been proposed, in which the full
distribution of participants’ outcomes in each group is
plotted. This approach visualizes the difference between
groups in the proportion of participants with a specific
outcome across the full range of possible outcomes allow-
ing for the difference between groups to be assessed at
any threshold for defining ‘‘response.’’6,19 Such an
approach mitigates the risks associated with relying on a
single threshold, although potentially allows increased
freedom for selective interpretation.An important limitation of our study is that it is
restricted to a convenience sample of data from a rela-
tively small number of trials of interventions for spinal
pain. We may have lacked adequate power to reliably
detect bimodality. Further analysis with data from a
larger set of trials for a broader range of interventions
and painful conditions would be useful. In addition, we
have focused on pain as a sole outcome and it is possible
that other important outcomes, for example, disability
or quality of life, may have shown different results.Conclusions
In a convenience sample of clinical trials of a variety of
conservative interventions for spinal pain we did not find
evidence that clinical outcomes were bimodally distrib-
uted. These findings suggest that bimodal distribution
of outcomes should not be assumed in interventions for
spinal pain and do not support the automatic prioritiza-
tion of responder analysis over the between group differ-
ence in the evaluation of treatment effectiveness for pain.
In light of this, a pragmatic approach for trialsmight be to
prospectively plan for either analysis approach, contin-
gent on the observed distribution of outcomes. We
note, however, that this approach is likely to have prac-
tical implications for study design and conduct, because
the required sample size for a responder analysis may be
much larger than that for a between group difference.
For systematic reviews of trials of interventions for pain,
when information regarding the distribution of outcomes
is likely to be missing in most cases and when individual
patient data are often not accessible, the decision is likely
to be driven by what is reported in the included studies.
There is a case for including both types of analysis.References
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